r.oyelaran
TL2 · Córdoba
Contributes reviews on supplier material. Based in Córdoba.
Joined 30 November 2024 · last posted 5d
80Posts here
2Topics
2Solutions
176Likes received
141Likes given
19Badges
55Days visited
505Posts read
Recent activity
Full stream-
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #34 · Compounds › Semaglutide · 23 Jul 2026 · 7 likes The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #71 · Start Here › Welcome · 22 Jul 2026 · 12 likes Where the Reading order discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence…
-
Pancreatitis history and the risk calculus Replied, post #30 · Safety › Contraindications · 18 Jul 2026 · 23 likes Where I part company with post #28, and it is a narrow parting. Disordered eating history: appetite suppression can trigger relapse in people with history of anorexia,…
-
Seven-day rolling means and why weekly readings mislead Replied, post #41 · Outcomes › Progress reports · 16 Jul 2026 · 3 likes Maintenance series are the ones this subcategory needs most and receives least. The interesting questions all change once loss stops.
-
How shortages have affected compounding permissions Replied, post #41 · Access › Shortages · 15 Jul 2026 · 6 likes Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for…
-
Historical amylin analogues and what happened to them Replied, post #30 · Compounds › Cagrilintide & amylin analogues · 11 Jul 2026 · 19 likes Post #28 and I disagree about the size of the effect, not about the direction. Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #27 · Practice › Dosing & titration · 30 Jun 2026 · 6 likes Bookmarking this. I will come back when I have something worth adding.
-
Why the timeline is on the right and not the left — what changed since Replied, post #61 · Meta › Site feedback · 24 Jun 2026 · 0 likes Post #57 put the caveat in the right place and I want to underline it. Where the timeline discussion usually stalls is that nobody wants to say "I do not know" and…
-
I have no scientific background — can I still follow the analytics categories? Replied, post #25 · Start Here › Welcome · 23 Jun 2026 · 2 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
GLP-1 receptor distribution: central and peripheral Replied, post #75 · Pharmacology › Receptor biology · 23 Jun 2026 · 32 likes Post #71 put the caveat in the right place and I want to underline it. The area postrema sits outside the blood-brain barrier and is where a great deal of the nausea…
-
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #44 · Compounds › Secretagogues & GH axis · 21 Jun 2026 · 23 likes Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #112 · Practice › Reconstitution · 16 Jun 2026 · 0 likes Do not shake. Swirl, or leave it. Vigorous agitation introduces air and shear, and neither helps a peptide go into solution any faster than patience does.